Citius Pharmaceuticals, Inc. (CTXR)

Market Cap	18.66M
Revenue (ttm)	n/a
Net Income (ttm)	-43.10M
Shares Out	11.17M
EPS (ttm)	-5.70
PE Ratio	n/a
Forward PE	1.03
Dividend	n/a
Ex-Dividend Date	n/a

Volume	304,173
Open	1.720
Previous Close	1.690
Day's Range	1.650 - 1.720
52-Week Range	0.650 - 26.250
Beta	1.23
Analysts	Strong Buy
Price Target	53.00 (+3,073.65%)
Earnings Date	Aug 11, 2025

About CTXR

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial fo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: CTXR
• Website: https://citiuspharma.com

Analyst Summary

According to 3 analysts, the average rating for CTXR stock is "Strong Buy." The 12-month stock price target is $53.0, which is an increase of 3,073.65% from the latest price.

Price Target

$53.0

(3,073.65% upside)

Analyst Consensus: Strong Buy